We appreciate the opportunity to provide a commentary on the article “The Effect of Antihypertensive Therapy on Skeletal Muscle Mass and Bone Mineral Density in Patients With End-Stage Kidney Disease” by Hashimoto et al.1 This study provides valuable insights into the complex relationship between antihypertensive therapy and musculoskeletal health in patients with end-stage kidney disease (ESKD). One intriguing finding is the potential effect of β-blockers in facilitating an annual loss of skeletal muscle mass, while renin–angiotensin–aldosterone system inhibitors (RASis), including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, may mitigate sarcopenia.